Names

    • Corynan-16-carboxylic acid, 19,20-didehydro-17-hydroxy-, methyl ester, (16R,19E)-
    • CS-0016094
    • SCHEMBL23675913
    • FS-8676
    • NSC 282700
    • DTXSID401317258
    • 16-epi-Isositsirikine
    • CHEMBL3940308
    • 16R,19E-isositsirikine
    • (16R)-E-Isositsirikine
    • HY-N0959
    • AKOS032948969
    • Q27138840
    • 16-Epi-isositsirikine
    • (16R,19E)-isositsirikine
    • methyl (2R)-2-[(2R,3E,12bS)-3-ethylidene-2,4,6,7,12,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-hydroxypropanoate
    • 6519-27-3
    • 17,18-Secoyohimban-16-carboxylic acid, 19,20-didehydro-17-hydroxy-, methyl ester, (16S,19E)-
    • Isositsirikine
    • NSC 338932
    • CHEBI:70508

Attributes

  • Canonical SMILES

  • InChI
  • Molecule Class:
  • TPSA:
  • #RotBonds:
  • MW:
  • HBD:
  • HBA:
  • logP:
  • Chemical Formula:


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. psorocarpa Ghana, Ivory Coast 761091 8134

External Databases


References

  • [12-Methoxy-17,18-dehydro-vincamine and 16-epi-isositsirikine, alkaloids from Tabernaemontana psorocarpa]. Planta Med, 1982 (PMID 17396949).
  • Alkaloids from Tabernaemontana psorocarpa. Planta Med, 1983 (PMID 17405098).

Compound-Protein Relationships

  • No relationship found

Compound Activities

  • No activity found

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -5.11
    Human Oral Bioavailability 20% Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney -5.03
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Non-Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability -2.02
    Distribution Blood-Brain Barrier (Central Nervous System) -2.6
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 0.83
    Plasma Protein Binding 56.83
    Steady State Volume of Distribution 5.27
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Non-Inhibitor
    CYP 1A2 substrate Substrate
    CYP 2C19 Inhibitor Inhibitor
    CYP 2C19 substrate Substrate
    CYP 2C9 Inhibitor Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Inhibitor
    CYP 2D6 Substrate Substrate
    CYP 3A4 Inhibitor Non-Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Non-Inhibitor
    Excretion Clearance 11.87
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Safe
    Bee Safe
    Bioconcentration Factor 0.27
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -0.88
    Liver Injury II Toxic
    hERG Blockers Toxic
    Daphnia Maga 5.54
    Micronucleos Toxic
    NR-AhR Toxic
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Safe
    T. Pyriformis -7.46
    Rat (Acute) 2.97
    Rat (Chronic Oral) 2.34
    Fathead Minnow 4.37
    Respiratory Disease Toxic
    Skin Sensitisation Safe
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 440.23
    Hydration Free Energy -7.29
    Log(D) at pH=7.4 2.71
    Log(P) 2.67
    Log S -3.24
    Log(Vapor Pressure) -9.33
    Melting Point 171.68
    pKa Acid 10.24
    pKa Basic 6.56